celecoxib has been researched along with Carcinoma, Adenosquamous in 3 studies
Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year." | 2.73 | A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K, 2007) |
| "Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy." | 2.73 | Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K, 2007) |
| "Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years." | 2.71 | Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. ( Ansari, R; Fineberg, N; Fox, E; Govindan, R; Hanna, N; Helft, P; Kesler, K; Mantravadi, P; McLeod, H; Stoner, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Govindan, R | 1 |
| McLeod, H | 1 |
| Mantravadi, P | 1 |
| Fineberg, N | 1 |
| Helft, P | 1 |
| Kesler, K | 1 |
| Hanna, N | 1 |
| Stoner, C | 1 |
| Ansari, R | 1 |
| Fox, E | 1 |
| Gaffney, DK | 2 |
| Winter, K | 2 |
| Dicker, AP | 2 |
| Miller, B | 2 |
| Eifel, PJ | 2 |
| Ryu, J | 2 |
| Avizonis, V | 2 |
| Fromm, M | 2 |
| Greven, K | 2 |
| Small, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for celecoxib and Carcinoma, Adenosquamous
| Article | Year |
|---|---|
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2004 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adeno | 2007 |
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2007 |